These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Re: Immediate versus Deferred Chemotherapy after Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-Label, Randomised Phase 3 Trial. Chang SS J Urol; 2016 Jan; 195(1):63-4. PubMed ID: 26699956 [No Abstract] [Full Text] [Related]
4. Comment re: Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial. Lancet Oncol 2015;16:76-86. Ohlmann CH; Stöckle M Eur Urol; 2015 Dec; 68(6):1104-5. PubMed ID: 26320378 [No Abstract] [Full Text] [Related]
5. A plea for uniform terminology for patients with urothelial carcinoma treated with chemotherapy prior to radical cystectomy: induction versus neoadjuvant chemotherapy. Liedberg F; Gudjonsson S; Kollberg P; Ullén A Eur Urol; 2015 Oct; 68(4):742-3. PubMed ID: 26047581 [No Abstract] [Full Text] [Related]
6. Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. Keck B; Wach S; Stoehr R; Kunath F; Bertz S; Lehmann J; Stöckle M; Taubert H; Wullich B; Hartmann A BMC Cancer; 2013 Feb; 13():71. PubMed ID: 23394492 [TBL] [Abstract][Full Text] [Related]
7. Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure. Necchi A; Raggi D; Giannatempo P; Alessi A; Serafini G; Colecchia M; Ali SM; Chung JH Eur J Cancer; 2018 Jun; 96():128-130. PubMed ID: 29680362 [No Abstract] [Full Text] [Related]
8. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Aparicio AM; Elkhouiery AB; Quinn DI Urol Clin North Am; 2005 May; 32(2):217-30, vii. PubMed ID: 15862619 [TBL] [Abstract][Full Text] [Related]
9. Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival. Fleischmann A; Thalmann GN; Perren A; Seiler R Am J Surg Pathol; 2014 Mar; 38(3):325-32. PubMed ID: 24525502 [TBL] [Abstract][Full Text] [Related]
10. [Adjuvant M-VEC in advanced urotheliomas of the bladder]. Cocimano V; Marino G; Brigato R; Pacilli N; Buffa G; Marten Perolino R Minerva Urol Nefrol; 1989; 41(3):195-7. PubMed ID: 2617375 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer. Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. Herr HW; Scher HI J Clin Oncol; 1994 May; 12(5):975-80. PubMed ID: 8164050 [TBL] [Abstract][Full Text] [Related]
13. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711 [TBL] [Abstract][Full Text] [Related]
14. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy? Tsai YS; Tzai TS; Chow NH Urol Int; 2007; 79(3):210-6. PubMed ID: 17940352 [TBL] [Abstract][Full Text] [Related]
16. The future of drug development in urothelial cancer. Dreicer R J Clin Oncol; 2012 Feb; 30(5):473-5. PubMed ID: 22184400 [No Abstract] [Full Text] [Related]